资讯

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Lantern Pharma Inc. ( NASDAQ: LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Panna Sharma - President & CEO David Margrave - CFO ...
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Lantern Pharma Earnings (LTRN) ...
KHON2 on MSN1 天
COVID on the Climb: Health Officials Urge Caution, Not Panic
It’s something many of us had hoped we’d left behind. But COVID-19 is making a quiet comeback across the islands. The state ...
CIDRAP6 天
US flu activity now at low levels, but CDC confirms 10 more kids' flu deaths
A 2024-25 flu season that has been classified as high severity has now reached low transmission levels, but 10 new ...
The Manila Times7 天
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies ...
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2025 and updated financial ...
Targeted Oncology9 天
FDA Clears LP-184 IND for TNBC Trial as Monotherapy & PARP Inhibitor Combo
A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.
LTRN: IND Clearance for LP-184 in TNBC
LTRN A May 5 th  press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...
Le Lézard10 天
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in ...
Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received ...